June 9, 2019 — Some of the most discussed news coming from the American Diabetes Association Scientific Sessions in San Francisco is all about the PIONEER studies of oral semaglutide. This drug is presently under review at FDA for type 2 diabetes. Interest is keen because it will be the first of its class that doesn’t require an injection. […]
June 29, 2016 — Late yesterday, expert advisors to the FDA voted by a margin of 12-11 that the diabetes drug Jardiance (emagliflozin) does indeed cut the risk of cardiovascular deaths for patients with type 2 diabetes who have a history of cardiovascular disease. The committee was unanimous in its agreement that the drug offers good cardiovascular safety. But […]
June 14, 2016 — A quiet revolution is taking shape in the form of weight-sparing diabetes care that helps people live longer. Yesterday new data were simultaneously published in the New England Journal of Medicine and presented at the American Diabetes Association (ADA) Scientific Sessions. The LEADER study showed that people treated for type 2 diabetes with liraglutide (Victoza) were 15% less […]
January 31, 2016 — Some big changes are in the wind for drugs that treat diabetes and obesity. The biggest selling diabetes drug in the world — Lautus — is facing competition from a lower-priced, biosimilar form of this long-acting form of insulin. Newer drugs like Jardiance (empagliflozin) and Victoza (liraglutide) are growing robustly, valued for their profile for […]
January 7, 2016 — A new review of advances in obesity care adds reasons to think that these advances are synergistic with advances in diabetes care. John Dixon highlights three major advances in obesity care from 2015 and all of them relate to diabetes as well. Liraglutide. Dixon cites impressive evidence that this drug, newly indicated for obesity treatment, is […]
September 19, 2015 — A remarkable study was published in the New England Journal of Medicine this week, demonstrating that type 2 diabetes care with an SGLT2 inhibitor (empagliflozin) both reduces weight and extends life. Of course, the most remarkable part of the study is the survival benefit that empaglifozin provides. In a randomized, placebo-controlled trial over just three years, the study […]
